MCEE and diabetic kidney disease: Emerging therapeutic agents for DKD, including liraglutide and canagliflozin, have been shown to activate AMPK and downstream MCE-related signaling pathways, highlighting the central role of MCE in metabolic regulation, inflammation resolution, and renal protection (58, 59).